Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
McKesson
Fish and Richardson
Boehringer Ingelheim
Fuji
Harvard Business School
Citi
Teva

Generated: August 18, 2018

DrugPatentWatch Database Preview

Albuterol sulfate; ipratropium bromide - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for albuterol sulfate; ipratropium bromide and what is the scope of albuterol sulfate; ipratropium bromide patent protection?

Albuterol sulfate; ipratropium bromide is the generic ingredient in four branded drugs marketed by Boehringer Ingelheim, Apotex Inc, Cipla Ltd, Fosun Pharma, Nephron, Ritedose Corp, Sun Pharma Global, Teva Pharms, Watson Labs Teva, and Mylan Speciality Lp, and is included in eleven NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Albuterol sulfate; ipratropium bromide has two hundred and ninety-one patent family members in forty-five countries.

There are thirty-eight drug master file entries for albuterol sulfate; ipratropium bromide. Sixteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for albuterol sulfate; ipratropium bromide
International Patents:291
US Patents:12
Tradenames:4
Applicants:10
NDAs:11
Drug Master File Entries: 38
Suppliers / Packagers: 16
Clinical Trials: 4
DailyMed Link:albuterol sulfate; ipratropium bromide at DailyMed
Pharmacology for albuterol sulfate; ipratropium bromide
Tentative approvals for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign UpEQ 0.083% BASE;0.017%SOLUTION;INHALATION

US Patents and Regulatory Information for albuterol sulfate; ipratropium bromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 077117-001 Dec 31, 2007 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fosun Pharma ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 076867-001 Dec 21, 2006 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for albuterol sulfate; ipratropium bromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim COMBIVENT albuterol sulfate; ipratropium bromide AEROSOL, METERED;INHALATION 020291-001 Oct 24, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for albuterol sulfate; ipratropium bromide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,084,461 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease ➤ Sign Up
6,503,440 Process for making a container with a pressure equalization opening and containers produced accordingly ➤ Sign Up
7,451,884 Container provided with a pressure equalization opening ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Dow
Daiichi Sankyo
US Department of Justice
Chinese Patent Office
McKesson
Cipla
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.